Jacob Van Naarden, Lilly Oncology
With Pazdur preparing to lower the boom on its PD-1, Eli Lilly spells out the deep discount on offer
Eli Lilly’s crew is walking into an adcomm Thursday where the key decision maker from the FDA — oncology czar Richard Pazdur — has clearly indicated he’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
